Celgene (CELG) Stock Rating Reaffirmed by BTIG Research

Celgene (NASDAQ:CELG)‘s stock had its “hold” rating reaffirmed by analysts at BTIG Research in a research report issued to clients and investors on Tuesday.

Several other analysts have also issued reports on the stock. Cantor Fitzgerald set a $112.00 price target on shares of Celgene and gave the stock a “hold” rating in a research report on Tuesday. BidaskClub lowered shares of Celgene from a “hold” rating to a “sell” rating in a research report on Saturday. Piper Jaffray Companies reissued a “hold” rating and issued a $104.00 price objective on shares of Celgene in a research report on Thursday, January 18th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $114.80 price objective on the stock in a research report on Wednesday, January 17th. Finally, Mizuho reissued a “buy” rating and issued a $128.00 price objective on shares of Celgene in a research report on Wednesday, January 17th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $129.98.

Shares of Celgene (NASDAQ:CELG) opened at $102.91 on Tuesday. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene has a 1 year low of $94.55 and a 1 year high of $147.17. The stock has a market cap of $81,020.00, a price-to-earnings ratio of 24.27, a price-to-earnings-growth ratio of 0.65 and a beta of 1.77.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the prior year, the firm posted $1.58 earnings per share. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. equities analysts anticipate that Celgene will post 6.71 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Beacon Capital Management acquired a new stake in shares of Celgene in the 4th quarter valued at approximately $0. Arcadia Investment Management Corp MI boosted its stake in shares of Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares in the last quarter. Thompson Davis & CO. Inc. boosted its stake in shares of Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares in the last quarter. Robecosam AG acquired a new stake in shares of Celgene in the 3rd quarter valued at approximately $114,000. Finally, Motco boosted its stake in shares of Celgene by 306.9% in the 1st quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 620 shares in the last quarter. 79.54% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/23/celgene-celg-stock-rating-reaffirmed-by-btig-research.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply